Cargando…
Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Prepared by a Joint Committee of the: Cancer Research Campaign National Institute for Biological Standards and Control.
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001634/ https://www.ncbi.nlm.nih.gov/pubmed/3756089 |
Ejemplares similares
-
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016) -
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019) -
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014) -
Advances in preclinical evaluation of experimental antibody-drug conjugates
por: Lyons, Scott K., et al.
Publicado: (2021) -
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
por: Barreca, Marilia, et al.
Publicado: (2022)